Synopsis
Join visionary bioengineer Don Ingber, MD, PhD and collaborators at Emulate’s headquarters for an exclusive, in‑person fireside chat on the FDA’s bold plan to phase out animal testing—and discover the breakthrough Organ‑Chip technology poised to lead that revolution. Sip craft cocktails and sample gourmet bites while getting a firsthand look at the brand new AVA Emulation System, a first-of-its-kind high-throughput Organ-Chip platform that will fundamentally transform how NAMs are deployed in preclinical drug development. Less than a mile from the Boston convention center, it’s the must‑attend BIO 2025 after‑hours event. RSVP now—space is limited!
Fireside Chat Panelists
- Don Ingber, MD, PhD, Founding Director of the Wyss Institute at Harvard University & Emulate Scientific Founder
- Lorna Ewart, PhD, Chief Scientific Officer, Emulate
- Samantha Atkins, PhD, Senior Scientist, Moderna
What to Expect
Welcome Reception, Networking, & Live Product Demos (5:00 – 6:00 PM)
Join the panelists, Emulate leadership, and fellow attendees for an invigorating cocktail hour accompanied by live product demonstrations. This is your chance to speak directly with Dr. Ingber as well as Drs. Ewart and Atkins ahead of the fireside chat!
Fireside Chat (6:00 – 7:00 PM)
Dr. Ingber, Dr. Ewart, and Dr. Atkins unpack the FDA’s groundbreaking roadmap to phase out animal testing and what it means for preclinical strategy and expedited IND reviews. Bring your questions—this is a rare chance to talk policy, science, and implementation with the visionaries driving the change.
Why Attend?
Timely. The FDA has signaled that by 2030 animal studies will be the exception, not the rule. Discover how to stay ahead.
Convenient. We’re just around the corner from the Boston Convention & Exhibition Center—easy to fit between BIO sessions and dinner reservations.
Exclusive. See technology and data that won’t be revealed anywhere else at BIO.
RSVP Required—space is limited.
We look forward to raising a glass with you and charting the next chapter of human‑centric drug development.
